D. E. Shaw & Co. Inc. Sells 792,731 Shares of Precigen, Inc. (NASDAQ:PGEN)

D. E. Shaw & Co. Inc. decreased its holdings in Precigen, Inc. (NASDAQ:PGEN) by 65.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 424,900 shares of the biotechnology company’s stock after selling 792,731 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.15% of Precigen worth $476,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Iridian Asset Management LLC CT boosted its holdings in shares of Precigen by 38.8% in the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock worth $5,871,000 after buying an additional 1,465,962 shares during the last quarter. Rhumbline Advisers raised its position in Precigen by 7.3% in the fourth quarter. Rhumbline Advisers now owns 197,134 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 13,338 shares during the period. Geode Capital Management LLC boosted its stake in shares of Precigen by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock worth $3,696,000 after acquiring an additional 53,343 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Precigen by 27.9% during the 4th quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 12,578 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Precigen by 28.3% during the 4th quarter. Barclays PLC now owns 242,899 shares of the biotechnology company’s stock valued at $272,000 after acquiring an additional 53,546 shares during the period. Institutional investors own 33.51% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PGEN. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Precigen in a research report on Thursday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Precigen in a research note on Thursday, May 15th. Finally, Wall Street Zen cut shares of Precigen from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Precigen has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Precigen Trading Down 1.4%

PGEN opened at $1.37 on Monday. The company has a market capitalization of $404.40 million, a price-to-earnings ratio of -2.49 and a beta of 1.82. Precigen, Inc. has a 12-month low of $0.65 and a 12-month high of $2.17. The business’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $1.32.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The business had revenue of $1.34 million for the quarter, compared to the consensus estimate of $0.50 million. On average, equities research analysts predict that Precigen, Inc. will post -0.32 EPS for the current year.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.